Amberstone and Henlius agree to develop solid-tumour T-cell engagers
Amberstone is eligible for up to $440m in development, regulatory and sales milestones for each target, with royalties.
Drug Development
FDA approves Lilly’s Onswik for type 2 diabetes in adults
Genialis and Inventia to enhance pancreatic cancer treatment testing
Basecamp Research secures $140m for AI-driven therapies
BoomRay and Novartis sign $900m deal for radioligand therapy
Boehringer and Envisagenics to develop precision cancer therapies in $1bn deal
Made Scientific acquires cell therapy facility in Pennsylvania, US
EC approves Menarini and NewAmsterdam’s obicetrapib therapies
